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Aim: Survivors of neonatal chronic lung disease or bronchopulmonary dysplasia
(BPD) suffer from compromised lung function and are at high risk for developing
lung injury by multiple insults later in life. Because neonatal lysophosphatidic acid
receptor-1 (LPAR1)-deficient rats are protected against hyperoxia-induced lung injury, we
hypothesize that LPAR1-deficiency may protect adult survivors of BPD from a second
hit response against lipopolysaccharides (LPS)-induced lung injury.
Methods: Directly after birth, Wistar control and LPAR1-deficient rat pups were exposed
to hyperoxia (90%) for 8 days followed by recovery in room air. After 7 weeks, male
rats received either LPS (2mg kg−1) or 0.9% NaCl by intraperitoneal injection. Alveolar
development and lung inflammation were investigated by morphometric analysis, IL-6
production, and mRNA expression of cytokines, chemokines, coagulation factors, and
an indicator of oxidative stress.
Results: LPAR1-deficient and control rats developed hyperoxia-induced neonatal
emphysema, which persisted into adulthood, as demonstrated by alveolar enlargement
and decreased vessel density. LPAR1-deficiency protected against LPS-induced lung
injury. Adult controls with BPD exhibited an exacerbated response toward LPS
with an increased expression of pro-inflammatory mRNAs, whereas LPAR1-deficient
rats with BPD were less sensitive to this “second hit” with a decreased
pulmonary influx of macrophages and neutrophils, interleukin-6 (IL-6) production, and
mRNA expression of IL-6, monocyte chemoattractant protein-1, cytokine-induced
neutrophil chemoattractant 1, plasminogen activator inhibitor-1, and tissue factor.
Chen et al. LPAR1-Deficiency Attenuates LPS-Induced Second-Hit Response
Conclusion: LPAR1-deficient rats have increased hyperoxia-induced BPD survival rates
and, despite the presence of neonatal emphysema, are less sensitive to an aggravated
“second hit” than Wistar controls with BPD. Intervening in LPA-LPAR1-dependent
signaling may not only have therapeutic potential for neonatal chronic lung disease, but
may also protect adult survivors of BPD from sequelae later in life.
Keywords: bronchopulmonary dysplasia, lung inflammation, adult rats, second hit response, aberrant lung
development, LPA receptor, LPS
INTRODUCTION
Very preterm infants are at high risk of developing severe
respiratory distress syndrome (RDS) secondary to lung
immaturity and surfactant-deficiency. Treatment with
mechanical ventilation and supplemental oxygen interferes with
postnatal lung development and damages the immature lung
(Northway et al., 1967; Baraldi and Filippone, 2007; Philip, 2009;
Bhandari, 2010; Mosca et al., 2011). Although, superb neonatal
intensive care after preterm birth increases survival, it cannot
prevent the development of neonatal chronic lung disease or
bronchopulmonary dysplasia (BPD), which is the most common
complication in children after preterm birth at <30 weeks of
gestation (Jobe, 1999; Gien and Kinsella, 2011; Mosca et al.,
2011; Jain and Bancalari, 2014). Severe BPD is characterized
by arrested alveolar and vascular development, resulting in
permanently enlarged alveoli, inflammation, and oxidative
stress-induced lung damage and is complicated by vascular
remodeling, which results in pulmonary arterial hypertension
(PAH) and right ventricular hypertrophy (RVH; Northway et al.,
1967; Mourani and Abman, 2015). Lung function in neonatal
survivors of BPD is not only affected directly after birth, but
also later in life, as these children are more susceptible to lower
respiratory tract infections, wheezing and asthma, and PAH at
relatively young ages (Bhandari and McGrath-Morrow, 2013;
Carraro et al., 2013; Gough et al., 2014). Their quality of life and
the burden to society of survivors of BPD is affected by frequent
rehospitalization after discharge and BPD-associated pathology,
such as poor neurodevelopmental outcome due to cerebral and
cerebellar hemorrhages and hypoxic insults, delayed growth,
and long-term gastro-intestinal problems (Dammann et al.,
2004). Treatment of BPD is mainly symptomatic and focuses on
gentler respiratory support to reduce neonatal lung damage and
pharmacological interventions, such as diuretics for lung edema,
caffeine to stimulate central respiratory drive, bronchodilators
for life-threatening episodes of severe bronchospasm, and
postnatal corticosteroids as anti-inflammatory agents (Baraldi
and Filippone, 2007; Gien and Kinsella, 2011; Jain and Bancalari,
2014).
The Lysophosphatidic acid (LPA) receptor 1 (LPAR1) pathway
has been considered a promising target for anti-fibrotic and
anti-inflammatory therapy in adult and neonatal lung disease
(Tager et al., 2008; Swaney et al., 2010; Rancoule et al.,
2011; Chen et al., 2016). LPA receptors (LPAR1-6) are 7-
transmembrane G protein-coupled receptors that are involved in
many biological and pathological processes after binding to their
ligand LPA (Yung et al., 2014). The glycerolipid LPA is generated
enzymatically through hydrolysis of lysophosphatidylcholine by
extracellular autotaxin (lysophospholipase D) or phospholipase
A1 or A2. Increased LPA and autotaxin expression is associated
with lung disease, including allergic asthma, fibrosis, and
experimental BPD (Oikonomou et al., 2012; Park et al., 2013;
Shim et al., 2015; Ackerman et al., 2016). Recently, Shim et al.
(2015) demonstrated that neonatal exposure to hyperoxia in
rat pups results in an increased expression and activity of the
important LPA generating enzyme autotaxin and expression of
the LPA receptors LPAR1 and LPAR3 compared to room air
controls. These data strongly suggest that exposure of neonatal
rat lungs to hyperoxia increases local LPA production and LPA-
dependent signaling that may contribute to BPD pathology. The
first identified LPA receptor with high affinity to LPA, LPAR1, or
endothelial differentiation gene (EDG) family member 2 (EDG2),
is expressed inmany organs, including lung and heart (Choi et al.,
2010). Reduced LPA-LPAR1-dependent signaling is associated
with beneficial effects in many pulmonary diseases, including
lung fibrosis, LPS-induced inflammation, bronchoconstriction,
airway hyper-responsiveness, and (experimental) BPD (Toews
et al., 2002; Tager et al., 2008; Swaney et al., 2010; Zhao et al.,
2011; Chen et al., 2016), demonstrating the therapeutic potential
of LPAR1 inhibition in adult and neonatal lung disease, including
BPD.
To develop novel treatment strategies for BPD, animal models
that mimic the clinical pathogenesis of BPD are mandatory
(Buczynski et al., 2013; Hilgendorff and O’Reilly, 2015). Because
rat and mouse pups are born at the saccular stage of lung
development, similar to preterm infants at risk for developing
BPD, alveolarization occurs after birth. Severe experimental BPD
can be induced in newborn rat pups by exposure to 100%
oxygen for 8 days, mimicking severe human BPD pathology
including persistent alveolar enlargement, caused by arrested
alveolar development and lung damage, inflammation, fibrosis
and PAH (Wagenaar et al., 2004, 2013; de Visser et al.,
2010; O’Reilly and Thébaud, 2014). In survivors of BPD, lung
pathology may be complicated by an aggravated response
toward a second hit. Mice with hyperoxia-induced BPD do
not only exhibit an aggravated second hit response to viral
infections, cigarette smoke, and bleomycin exposure, but their
life span was also shorter (O’Reilly et al., 2008; McGrath-
Morrow et al., 2011; Yee et al., 2011, 2013; Maduekwe et al.,
2015). However, in rat models these aggravated responses
toward a second hit remain to be elucidated. In a previous
study, we demonstrated that blocking of LPAR1-dependent
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signaling, either by pharmacological intervention or by studying
LPAR1-deficient rats, might be an effective treatment option
for BPD by preventing inflammation-dependent lung injury.
This was demonstrated by a reduced influx of macrophages and
neutrophils, inflammatory cytokines production, and collagen
deposition in the lung (Chen et al., 2016). Furthermore, the role
of LPAR1-deficiency on the pathogenesis of a second hit response
in survivors of BPD is unknown. This prompted us to investigate:
[1] the role of LPAR1-deficiency on normal lung development,
[2] the acute inflammatory response to LPS of adult rat survivors
of BPD, and [3] the beneficial effects of LPAR1-deficiency on the
development of a second hit response against LPS-induced acute
lung injury in adult rats with hyperoxia-induced BPD.
MATERIALS AND METHODS
Animals
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the Leiden University
Medical Center. LPAR1-mutant rats, generated by N-ethyl-
N-nitrosourea mutagenesis, carry a missense mutation with
a methionine instead of arginine at position 318 in the
cytoplasmic 8th helix, resulting in a loss-of-function phenotype
(van Boxtel et al., 2011; Chen et al., 2016). LPAR1-deficient
(LPAR1M318R/M318R) rats were back-crossed for 11 generations
on a Wistar rat background. For each experiment, newborn male
Wistar or LPAR1-deficient (homozygous LPAR1M318R/M318R) rat
pups from 3 to 5 litters were mixed together and equally assigned
to 2 experimental groups: oxygen group (N = 12) and two
room air (RA) groups (N = 6 each). First hit: the pups were
exposed to 90% O2 from days 1 to 9 after birth (Figure 1A). All
pups were fed by foster dams who were rotated daily to avoid
oxygen toxicity: 24 h in 90% oxygen and 48 h in RA. Oxygen
concentration, body weight, evidence of disease, and mortality
were recorded daily. On day 9, the oxygen concentration was
decreased to 75% and on day 10, pups were moved to room
air. At the age of 7 weeks (body weight: 225–235 g), survivors
of hyperoxia-induced BPD and RA controls were divided ad
random into two groups: [1] second hit by intraperitoneal
injection of 2mg kg−1 of Lipopolysaccharides (LPS extracted
from Pseudomonas aeruginosa, L9143, Sigma-Aldrich, St. Louis,
MO, USA) in 1.5ml 0.9% NaCl, or [2] injection with an equal
volume of 0.9% NaCl (Figure 1A). Body weight of all rats
from 8 experimental groups was measured 24 h after injection
(Figures 1A,B). Hereafter, rats were anesthetized with isoflurane
inhalation and sacrificed by exsanguination to collect lung tissue.
From each animal, the right lung was frozen in liquid nitrogen
for RT-PCR, and the left lung was fixed in situ by perfusion with
4% paraformaldehyde (PFA) for 6 min at a pressure of 11 cm
H2O for histology (N = 7). In total, we studied 3 variables in 8
experimental groups (parameters (Figure 1B): [1] hyperoxia vs.
room air, [2] LPAR1 deficiency vs. Wistar control, and [3] LPS vs.
NaCl).
Histology
Formalin-fixed, paraffin-embedded, 4µm-thick lung sections
were stained with hematoxylin and eosin, anti-ED-1 (monocytes
A
B
FIGURE 1 | The second hit hypothesis of bronchopulmonary dysplasia
(BPD) was tested in Wistar control and Lysophosphatidic acid 1
(LPAR1) deficient rats: LPAR1M318R/M318R (LPAR1M). Directly after birth,
rat pups were exposed to 90% oxygen for 9 days (first hit) to induce
experimental BPD (A). At the age of 7 weeks, adult male rats were treated with
LPS (2mg kg−1) or 0.9% NaCl as a control by intraperitoneal injection to
induce acute lung injury (second hit). In total, we studied 3 variables ([1]
hyperoxia vs. room air, [2] LPAR1 deficiency vs. Wistar control, and [3] LPS vs.
NaCl) in 8 experimental groups (B). Rats with experimental hyperoxia-induced
BPD are depicted by shaded bars and room air (RA) controls are depicted by
white bars.
and macrophages; diluted 1:5), anti-myeloperoxidase (MPO,
RB-373-A1, Thermo Fisher Scientific, Fremont, CA, USA;
diluted 1:1,500) and anti-von Willebrand factor (vWF, A0082,
Dako Cytomation, Glostrup, Denmark; diluted 1:4,000).
Primary antibody staining was visualized with Envision-HRP
(K4001/K4003, Dako North America, Carpinteria, CA, USA)
and NovaRed (SK-4800, Vector Laboratories, Burlingame
CA, USA) as suggested by the supplier and counterstained
briefly with hematoxylin. For morphometry of the lung, an
eyepiece reticle with a coherent system of 21 lines and 42 points
(Weibel type II ocular micrometer; Olympus, Zoeterwoude, The
Netherlands) was used (Wagenaar et al., 2004). To investigate
whether the enlarged alveoli in neonatal BPD persist into
adulthood, we studied mean linear intercept (MLI), determined
on hematoxylin and eosin stained lung sections, in 10 non-
overlapping fields at a 200x magnification for each animal
(Dunnill, 1962). The density of ED-1 positive monocytes
and macrophages or MPO-positive neutrophilic granulocytes
was determined in the alveolar compartment by counting
the number of cells per field. Results were expressed as cells
per mm2. Twenty fields in one section were studied at a
400x magnification. Capillary density was assessed in lung
sections stained for vWF at a 200x magnification by counting
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the number of vessels per field. At least 10 representative
fields per experimental animal were investigated. Results
were expressed as relative number of vessels per mm2. Two
independent researchers, who were blinded to the treatment
strategy, performed lung morphometric analysis as described
in previous studies (de Visser et al., 2010; Chen et al., 2015,
2016).
Elisa
IL-6 levels were determined in lung tissue homogenates by
ELISA (RRF600CKX, Antigenix America, Huntington Station,
NY, USA) according to the instructions provided by the
manufacturer.
Real-Time RT-PCR
Real-time quantitative PCR was performed on a Light Cycler
480 (Roche, Almere, The Netherlands) at the Leiden Genome
Technology Center (Leiden, The Netherlands), using first-strand
cDNA synthesized from total RNA (SuperScript Choice System;
Life Technologies, Breda, the Netherlands) and β-actin as a
reference gene as previously described (Wagenaar et al., 2004).
RNA was isolated from lung tissue homogenates (RNA-Bee,
Tel-Test Inc, Bio-Connect BV, Huissen, the Netherlands), as
described previously (Wagenaar et al., 2004, 2013). Primers are
listed in Table 1.
Statistical Analysis
Values are expressed as mean ± SEM. Differences between
groups were analyzed by one-way ANOVA for independent
samples, followed by Tukey’s multiple comparison test, using the
GraphPad Prism version 6 software package (San Diego, CA,
USA). Differences at a p < 0.05 were considered statistically
significant.
RESULTS
Dosage Finding for LPS-Induced Lung
Injury in Adult Rats
We performed a pilot study to determine the optimal dose of
LPS to induce acute lung inflammation. Male Wistar rats (mean
230 g) were injected intraperitoneally with 2, 4, or 6mg kg−1
of LPS or 0.9% NaCl. Survival and influx of macrophages and
neutrophils into the lung were quantified as read-outs (Figure 2).
Because 6mg kg−1 of LPS led to a mortality rate of 50%, this
dosage of LPS was considered inappropriate (Figure 2G). All rats
injected with 0.9%NaCl, or 2 or 4mg kg−1 LPS survived. Because
the inflammatory response, determined by the massive LPS-
induced influx of ED1-positive macrophages (Figures 2B,C,H)
and MPO-positive neutrophils (Figures 2E,F,I) was similar after
administration of LPS doses of 2 and 4mg kg−1, we decided that
2mg kg−1 of LPS was the optimal dose.
LPAR1-Deficiency Protects against
Neonatal Hyperoxia-Induced Mortality
Exposure to hyperoxia for 8 days significantly decreased body
weight of Wistar pups (mean 13.5 g; p < 0.01) and LPAR1
deficient pups (12.4 g; p < 0.05), compared to their room air-
exposed controls (Wistar: 19.3 g and LPAR1: 18.3 g; Figure 3A).
All pups survived in room air. Mortality in Wistar pups exposed
to hyperoxia for 8 days was twice as high as in RA controls (p <
0.01) and also exceeded mortality in LPAR1-deficient pups (p <
0.05 compared to Wistar pups exposed to hyperoxia; Figure 3B).
LPAR1-Deficiency Results in Emphysema
in Adult Rats
Seven weeks old adult LPAR1-deficient rats had enlarged
alveoli (Figure 4B) as shown by an increased mean linear
intercept (MLI; 1.2-fold; p < 0.01; Figure 4I) and decreased
vascularization (1.1-fold; p < 0.01; Figures 4F,J) compared
to Wistar controls (Figures 4A,E,I,J). LPS had no effect on
alveolar enlargement and vascularization in Wistar controls, but
aggravated the increase in alveolar size (p < 0.05) and reduction
in vascularization (p < 0.01) in LPAR1-deficient rats compared
to RA-LPAR1M-NaCl controls.
Hyperoxia-Induced Neonatal Emphysema
and Reduced Angiogenesis Persists into
Adulthood
Adult survivors of BPD showed alveolar enlargement and
reduced vascularization, demonstrated by an increased MLI (1.4-
fold, p < 0.001; Figures 4C,I) and a decreased number of blood
vessels (1.1-fold, p < 0.01; Figures 4G,J), respectively compared
to RA-exposed controls (Figures 4A,E), demonstrating
persistent emphysema and reduced vascularization in survivors
of BPD. LPS administration had no impact on MLI (Figure 4I),
but reduced pulmonary vessel density by 1.1-fold (Figure 4J),
compared to LPS-stimulated Wistar (p < 0.05) or NaCl-treated
TABLE 1 | Sequences of oligonucleotides for forward and reverse primers for real-time RT-PCR.
Gene product Forward primer Reverse primer
IL-6 5′-ATATGTTCTCAGGGAGATCTTGGAA-3′ 5′-TGCATCATCGCTGTTCATACAA-3′
CINC1 5′-GCACCCAAACCGAAGTCATA-3′ 5′-GGGGACACCCTTTAGCATCT-3′
MCP-1 5′-ATGCAGTTAATGCCCCAGTCA-3′ 5′-TTCTCCAGCCGACTCATTGG-3′
PAI-1 5′-AGCTGGGCATGACTGACATCT-3′ 5′-GCTGCTCTTGGTCGGAAAGA-3′
TF 5′-CCCAGAAAGCATCACCAAGTG-3′ 5′-TGCTCCACAATGATGAGTGTT-3′
HMOX1 5′-GACAGCATGTCCCAGGATTT-3′ 5′-CTGGACACCTGACCCTTCTG-3′
β-actin 5′-TTCAACACCCCAGCCATGT-3′ 5′-AGTGGTACGACCAGAGGCATACA-3′
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A B C
D E F
G H I
FIGURE 2 | The optimal dose of LPS to induce acute lung inflammation was investigated in a pilot experiment using adult Wistar rats, injected once
with 0.9% NaCl or LPS at dosages of 2, 4, or 6mg kg−1. Twenty-four hours after injection, survival was recorded (G) and rats were sacrificed. Representative
lung sections stained for the macrophage marker ED1 (A–C) and neutrophilic granulocyte marker MPO (D–F) were quantified in (H) (macrophages) and (I)
(neutrophils) in rats injected with 0 (NaCl control), 2 or 4mg kg−1 of LPS. Values were expressed as mean ± SEM, N = 6. ***p < 0.001 vs. NaCl control. a, alveolus.
LPAR1-deficient rats with hyperoxia-induced BPD (p < 0.01;
Figures 4D,H).
LPAR1-Deficiency Protects against
LPS-Induced Pulmonary Influx of
Inflammatory Cells and IL-6 Expression
Adult Wistar control and LPAR1-deficient rats were raised
in RA after birth and developed a significant inflammatory
response toward LPS. This was demonstrated by an influx of
macrophages (p< 0.001; Figures 5E,F,I), neutrophils (p< 0.001;
Figure 5J), and increased expression of interleukin 6 at the
protein level IL-6; p < 0.05; Figure 5K), compared to NaCl-
treated controls (Figures 5A,B). The LPS-induced pulmonary
influx of macrophages (1.3-fold; p < 0.01) and neutrophils (1.6-
fold; p < 0.01) and IL-6 protein expression (1.3-fold; p < 0.05)
was significantly reduced in LPAR1-deficient rats compared to
LPS-stimulated Wistar control rats.
LPAR1-Deficiency Attenuates the Adult
LPS-Induced Inflammatory Second Hit
Response
Neonatal exposure to hyperoxia led to a transient inflammatory
response characterized by an influx of macrophages and
neutrophils in neonatal rat lung, which did not persist
into adulthood (Figures 5C,D,I,J). Administration of LPS did
not aggravate the influx of macrophages (Figures 5G,I) and
neutrophils (Figure 5J), and IL-6 expression (Figure 5K) in
survivors with BPD compared to RA-exposed Wistar controls.
However, in adult LPAR1-deficient rats with BPD the LPS-
induced influx of macrophages (Figures 5H,I) and neutrophils
(Figure 5J) in lung tissue sections and the level of IL-6 in lung
tissue homogenates (Figure 5K) were lower compared to Wistar
rats with BPD: 2.4-fold, p< 0.001 for macrophages; 2.1-fold, p<
0.05 for neutrophils; and 2.2-fold, p < 0.001 for IL-6 expression.
In addition, the basal level of IL-6 in the BPD lung was higher
in Wistar rats than in LPAR1-deficient rats (1.4-fold, p < 0.05;
Figure 5K).
LPAR1-Deficiency Attenuates the
Aggravated Pro-inflammatory and
Pro-coagulant Second Hit Response
toward LPS in Adult Rats with BPD at the
Transcriptional Level
The basal mRNA expression (Figure 6) of IL-6 (Figure 6A),
MCP-1 (Figure 6B), CINC1 (Figure 6C), PAI-1 (Figure 6D),
tissue factor (TF; Figure 6E), and Heme Oxygenase 1 (HMOX1;
Figure 6F) was comparable in Wistar rats with and without BPD
and in LPAR1-deficient rats with BPD except for IL-6. Basal
IL-6 expression was lower in LPAR1-deficient rats with BPD
(p < 0.01), compared to adult Wistar controls with BPD. In
control Wistar rats, LPS stimulated mRNA expression of IL-6
(75.9-fold; p < 0.001), MCP-1 (12.9-fold; p < 0.001), CINC1
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A B
FIGURE 3 | Body weight (A) and survival (B) of Wistar and LPAR1-deficient (LPAR1M318R/M318R ) pups after 8 days in RA (open bars) and exposure to hyperoxia
(shaded bars). Values were expressed as mean ± SEM, N = 7–10. *p < 0.05 and **p < 0.01 vs. their own RA control.
†
p < 0.05 vs. Wistar controls with neonatal
chronic lung disease or BPD. Three independent experiments were performed.
(10.7-fold; p < 0.001), PAI-1 (4.8-fold; p < 0.001), and HMOX1
(3.6-fold; p < 0.001) compared to NaCl-treated Wistar controls.
LPS-inducedmRNA expression of IL-6,MCP-1,CINC1, and PAI-
1 in adult LPAR1-deficient and in Wistar control rats was not
significantly different, but there was a tendency toward higher
levels in LPAR1-deficient rats.
Neonatal exposure to hyperoxia aggravated the LPS-induced
second hit response in adult rat lung for IL-6 (5.7-fold; p< 0.05),
PAI-1 (3.0-fold; p < 0.05), and TF (2.1-fold; p < 0.001), whereas
MCP-1 and CINC1 showed a tendency toward higher levels,
compared to LPS-stimulated RA Wistar controls. The second
hit response toward LPS was prevented in LPAR1-deficient rats
with BPD for IL-6 (12.0-fold; p < 0.001), MCP-1 (3.6-fold; p <
0.01), PAI-1 (5.1-fold; p < 0.001), and TF (1.5-fold; p < 0.01),
whereas CINC1 showed a tendency toward lower levels than
LPS-stimulated Wistar rats with BPD. The LPS response toward
HMOX1 expression was not affected by exposure to hyperoxia or
LPAR1-deficiency.
DISCUSSION
This study demonstrates that [1] acute lung injury in adulthood
induces an aggravated second hit response in rats with
neonatal hyperoxia-induced BPD, [2] LPAR1-deficiency results
in emphysema and reduced vascularization in adult rats, and
[3] LPAR1-deficient rats with BPD are protected against the
exacerbated second hit response induced by LPS. The persistence
of emphysema and reduced vascularization resulting from
neonatal exposure to hyperoxia is consistent with our previous
finding in the same BPD rat model (de Visser et al., 2012).
We found that LPAR1-deficiency leads to alveolar
enlargement or emphysema and decreased pulmonary vessel
density in adult rats. This finding confirms observations
in LPAR1 knockout mice showing that aberrant alveolar
development caused by reduced secondary septation during
early lung development was visible from 3 weeks after birth until
adulthood (Funke et al., 2016). This explains why we did not
observe alveolar enlargement in our previous study, in which the
effects of LPAR1-deficiency on aberrant lung development were
limited to the early neonatal period (Chen et al., 2016). LPAR1-
deficiency may contribute to arrested alveolar development and
reduced secondary septation by remodeling of elastic fibers,
resulting in a reduction of disorganized septal fibers (Funke
et al., 2016). The adverse effect of LPAR1 deficiency on alveolar
development may limit the clinical usage of LPAR1 inhibitors for
BPD. However, in LPAR1 deficient rats LPA-LPAR1 dependent
signaling is reduced during pre- and postnatal development,
whereas inhibition of the LPA-LPAR1 pathway is likely only
needed during the relatively short pulmonary injurious period
of mechanical ventilation with supplemental oxygen. Therefore,
the adverse effect of a potent LPAR1 blocker on adverse alveolar
development will probably be less severe when used postnatally
in premature infants with BPD, thereby limiting the adverse
effects on emphysema development in adult survivors of BPD.
Exposure to hyperoxia or air pollution induces oxidative
stress and generates cytotoxic reactive oxygen species (ROS)
in lung cells. ROS, either generated directly or indirectly
by activated inflammatory cells, can cause epithelial and
endothelial cell injury and death by activation of complex
signal transduction pathways and epigenetic factors (Hagood,
2014; Ni et al., 2015; Porzionato et al., 2015). Oxidative stress
after LPS stimulation was demonstrated in this study by an
increase in expression of HMOX1. In neonatal chronic lung
disease (BPD), adult chronic obstructive pulmonary disease
(COPD), and LPS-induced acute lung injury oxidative stress
activates multiple signal transduction pathways that belong to
the mitogen-activated protein kinases (MAPK) family, including
extracellular signal-regulated kinase (ERK1/2), C-Jun-terminal
protein kinase (JNK1/2) and p38 kinase, and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) (Ryter
et al., 2007; Zuo et al., 2012; Porzionato et al., 2015). Activation
of ERK protects lung cells against hyperoxia-induced injury
and death through stimulation of DNA repair and anti-oxidant
mechanisms, whereas activation of JNK1/2, p38 kinase and NF-
κB is associated with adverse effects, including tissue damage via
necrosis and apoptosis, TGF-β-induced aberrant alveolarization
and activator protein-1-induced inflammation. In addition, ROS
may contribute to disease pathology by epigenetic effects via
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FIGURE 4 | Representative HE-stained (A–D) and von Willebrand factor (vWF)-stained (E–H) lung paraffin sections of adult Wistar rats (A,C,E,G) and
LPAR1-deficient (LPAR1M318R/M318R ) rats (B,D,F,H) injected with 0.9% NaCl (A–D) or 2mg kg−1 of LPS (E–H). Quantifications of mean linear intercept (I) and
number of pulmonary vessels (J) were determined on sections in Wistar and LPAR1-deficient rats with neonatal chronic lung disease or BPD (shaded bars) or RA
controls (white bars). Values are expressed as mean ± SEM, N = 7. *p < 0.05 and **p < 0.01 vs. their own NaCl controls. 11p < 0.01 and 111p < 0.001 vs.
RA-NaCl control,
†
p < 0.05 vs. Wistar rats with BPD. $$p < 0.01 and $$$p < 0.001 vs. their own RA controls. Three independent experiments were performed. a,
alveolus. Arrows in panels (E–H) indicate vWF-stained blood vessels.
histone modification, RNA interference, and DNA methylation
(Hagood, 2014). In mammals, neonatal oxidative stress, induced
by prolonged exposure to hyperoxia, disrupts alveolar and
vascular development of the immature lung, which results in
enlarged alveoli, increased septal thickness, pulmonary influx of
inflammatory cells, including macrophages and neutrophils, and
vascular remodeling (Madurga et al., 2013).
In agreement with our previous studies, we found that
neonatal hyperoxia-induced emphysema persists into adulthood
(de Visser et al., 2012) and confirm similar observations in
mice with BPD (O’Reilly et al., 2008; McGrath-Morrow et al.,
2011). Furthermore, this study shows for the first time in
rats that the inflammatory second hit response is aggravated
in survivors of BPD after administration of LPS. These data
confirm previous observations in mice with BPD that showed an
exacerbated second hit response to exposure to cigarette smoke-
induced emphysema, viral infection, and bleomycin-induced
lung fibrosis (O’Reilly et al., 2008; McGrath-Morrow et al., 2011;
Yee et al., 2013). Collectively, these findings demonstrate lung
hyper-responsiveness to viral and toxic insults in rodents with
hyperoxia-induced BPD.
The second hit response in adult rats with BPD was clearly
demonstrated at the mRNA level by an increased expression of
the pro-inflammatory marker IL-6, the procoagulant gene TF
and the regulator of fibrinolysis PAI-1, but was less pronounced
or even absent at the protein level. This discrepancy in
second hit response at the protein level between our study
and the previously published mouse studies may be attributed
to differences in species, injurious trigger, sampling, and a
more pronounced effect at the transcriptional level due to the
experimental setup. We studied acute lung pathology at 24 h
after LPS stimulation with a relatively high dose of LPS (2mg
kg−1) to induce lung injury, whereas in mice chronic lung
diseases were studied for weeks, including cigarette smoke-
induced emphysema, viral infection, and bleomycin-induced
lung fibrosis (O’Reilly et al., 2008; McGrath-Morrow et al., 2011;
Yee et al., 2013).
The LPA-LPAR1 pathway has been regarded as a promising
target for anti-fibrotic and anti-inflammatory therapy (Tager
et al., 2008; Swaney et al., 2010; Rancoule et al., 2011).
We demonstrated that LPAR1-deficiency reduces the influx of
inflammatory cells and IL-6 after a LPS challenge in adult rats
and, more effectively, the second hit response against LPS in
adult rats with neonatal chronic lung disease or BPD, in which
not only the influx of inflammatory cells and IL-6 was strongly
reduced, but also the mRNA expression of IL-6, MCP-1, CINC1,
TF, and PAI-1. In previous work, we found that pharmacological
blocking of the LPA-LPAR1 signaling pathway with Ki16425
protected against BPD in neonatal rat pups (Chen et al.,
2016). However, the role of LPA/LPAR1-dependent signaling in
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FIGURE 5 | Representative lung paraffin sections stained for the macrophage marker ED1 in rats injected with 0.9% NaCl (A–D) or 2mg kg−1 of LPS
(E–H). Quantification of macrophages (I) and neutrophils (J) on sections and IL-6 ELISA (K) in lung homogenates were determined in Wistar and LPAR1-deficient
(LPAR1M318R/M318R ) rats with neonatal chronic lung disease or BPD (shaded bars) or RA controls (white bars). Values are expressed as mean ± SEM, N = 7. *p <
0.05 and ***p < 0.001 vs. their own NaCl controls.
†
p < 0.05,
††
p < 0.01, and
†††
p < 0.001 vs. Wistar rats with BPD. Three independent experiments were
performed. a, alveolus. Arrows indicate ED1-positive macrophages.
pulmonary inflammation is still controversial. Although, LPS
increases LPA in plasma (Zhao et al., 2011; Awada et al., 2014;
Mouratis et al., 2015), suggesting a role for LPA-LPAR1 signaling
in the LPS response, in vitro and in vivo data demonstrate that
both stimulation (Murch et al., 2007; Fan et al., 2008; He et al.,
2009; Zhao et al., 2012) and inhibition (Zhao et al., 2011; Chen
et al., 2016) of this pathway result in a reduced inflammatory
response. Here, we found that the beneficial effects of LPAR1-
deficiency are not only limited to the neonatal period (Chen
et al., 2016), because LPAR1-deficiency ameliorated the LPS-
induced second hit response in adult survivors of BPD. LPAR1-
deficient rats showed a reduced infiltration of macrophages
and neutrophils into the lung, IL-6 protein expression and IL-
6, MCP-1, CINC1, PAI-1, and TF mRNA expression in the
lung during a second hit. The disparities in the effect of LPA-
LPAR signaling on inflammation may be due to differences in
gene regulation at the transcriptional and post-transcriptional
level, experimental setup, including differences in inflammatory
parameters studied at different time points, LPA receptors, cell
types, and background (Chu et al., 2015).
LPAR1 is a 7-transmembrane G protein-coupled receptor
(GPCR) that couples with three types of G proteins after binding
to its ligand LPA: Gα12/13, Gαq/11, Gαi/o, resulting in the
initiation of many downstream signaling cascades, including the
Rho-ROCK, phospholipase C, Ras, P38-MAPK, Akt, and NF-κ B
pathway and inhibition of adenylyl cyclase (AC) (Lin et al., 2010;
Zhao et al., 2011; Yung et al., 2014). Many of these pathways are
also affected in the pathogenesis of hyperoxia-induced neonatal
lung injury, including AC-, activator protein 1 (AP1)-, P38
MAPK-, NF-κB-, and akt-dependent signaling (Perkowski et al.,
2003;Wagenaar et al., 2004; Porzionato et al., 2015). This suggests
that the beneficial effects of LPAR1 inhibition on ROS- and
inflammation-driven lung injury and fibrosis is very complex and
may be explained by reduced LPAR1-dependent signaling via
multiple signal transduction pathways or cAMP via activation
of AC. The beneficial effect of LPAR1-deficiency on the LPS
response in rats with BPD is further complicated by the biological
response of LPAR1-deficiency on two different injurious stimuli,
inflicted at two different time-points, i.e., hyperoxia-induced
lung injury in the neonatal period and LPS-exposure during
adulthood. Several studies have provided preliminary data on the
mechanism by which LPA-LPAR blocking protects against lung
injury after a single injurious response caused by either hyperoxia
or LPS. Hyperoxia-induced lung inflammation is associated with
an increased expression of autotoxin, LPAR1, and LPAR3 in
neonatal rats (Shim et al., 2015) and is stimulated by LPA-
dependent activation of natural killer T (NKT) cells in adult
mice (Nowak-Machen et al., 2015). Furthermore, blocking of
LPA/LPAR-dependent signaling reduces LPS-induced lung injury
by attenuating the activation of p38 MAPK and NF-κB and
IL-6 production in adult mice (Zhao et al., 2011). However,
mechanistic data on the response of a second hit by LPS after
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FIGURE 6 | Relative mRNA expression of interleukin 6 (IL-6; A), monocyte chemoattractant protein-1 (MCP-1; B), cytokine-induced neutrophil chemoattractant
1 (CINC1; C), plasminogen activator inhibitor-1 (PAI-1; D), tissue factor (TF; E) and Heme Oxygenase 1 (HMOX1; F) in lung homogenates of adult Wistar and
LPAR1-deficient (LPAR1M318R/M318R ) rats with neonatal chronic lung disease or BPD (shaded bars) or Wistar RA controls (white bars), injected with 0.9% NaCl or
2mg kg−1 of LPS, using β-actin as a house keeping gene reference. Values are expressed as mean ± SEM, N = 7. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. their
own NaCl controls.
††
p < 0.01 and
†††
p < 0.001 vs. Wistar rats with BPD. $p < 0.05 and $$$p < 0.001 vs. Wistar RA control rats. Three independent experiments
were performed.
hyperoxic lung injury are lacking. Therefore, additional studies
are needed to elucidate the complex mechanisms by which
LPAR1 blocking protects against LPS-induced lung injury in rats
with BPD.
In summary, the current study shows that, similar to humans
and mice, lungs of adult rats that survived BPD are hyper-
responsive to a second hit. Furthermore, deficiency of LPAR1
attenuates the inflammatory response to a second hit in adult
rats with BPD. These findings extend our previous work by
showing that LPAR1 blocking not only protects against neonatal
hyperoxia-induced BPD, but also has additional long-term
beneficial effects on the response to insults later in life. Therefore,
blocking the LPA-LPAR1 signaling pathway may be a promising
pharmaceutical target for the treatment of BPD and prevention
of its sequelae later in life.
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